BiotechTube

turoctocog alfa pegol

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Congenital Bleeding Disorder

Conditions

Congenital Bleeding Disorder, Haemophilia A

Trial Timeline

Jan 30, 2012 → Dec 10, 2018

NCT ID
NCT01480180

About turoctocog alfa pegol

turoctocog alfa pegol is a phase 3 stage product being developed by Novo Nordisk for Congenital Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01480180. Target conditions include Congenital Bleeding Disorder, Haemophilia A.

What happened to similar drugs?

5 of 20 similar drugs in Congenital Bleeding Disorder were approved

Approved (5) Terminated (0) Active (15)
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved
✅activated recombinant human factor VII + activated recombinant human factor VII + factor VIIINovo NordiskApproved
✅Lipiodol Ultra Fluid with surgical gluesGuerbetApproved
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (8)

NCT IDPhaseStatus
NCT04334057Pre-clinicalCompleted
NCT04682145Pre-clinicalRecruiting
NCT02994407Phase 1Completed
NCT02920398Phase 1Completed
NCT02137850Phase 3Completed
NCT01731600Phase 3Completed
NCT01489111Phase 3Completed
NCT01480180Phase 3Completed

Competing Products

20 competing products in Congenital Bleeding Disorder

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29
nonacog beta pegolNovo NordiskPhase 3
40